Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis

This is a Phase 2, multicenter, randomized, double‐blind, parallel group, placebo‐controlled study to investigate the safety, tolerability, efficacy and dose‐response of GSK2831781 in participants with moderate to severe active ulcerative colitis. The study consists of a 5‐week screening window, 10‐week Induction Phase, 30‐week double‐blind Extended Treatment Phase (ETP) with 42‐week Follow‐Up Phase. Non‐Responders identified following the Week 10 assessment will be allocated to open label treatment, consisting of Induction (Weeks 12 to 22), an Open label ETP (Weeks 22 to 42) and a follow‐Up to Week 54.